Tools   Select Another Resource Report Type

http://www.atsfoundation.org/

A non-profit organization that facilitates the donation of tissues. It supports healthcare agencies, coroners, medical examiners and funeral professionals through donations and training, as well as partnering with organizations that utilize tissue in medical care and research.

Proper citation: American Tissue Services Foundation - ATSF (RRID:SCR_000549) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29346&a=31576&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 23, 2016. PRACSIS (Prognosis and Risk in Acute Coronary Syndromes In Sweden) aims to study prognosis and its predictors in a consecutive series of patients with acute coronary syndrome (ACS). The study is comprised of patients between 18 and 80 years diagnosed at the coronary care unit at the Sahlgrenska University Hospital with unstable angina, non-ST-elevation MI or ST-elevation MI. Extensive information on medical history and blood samples for analyses of biochemical markers and genetic factors have been collected.

Proper citation: PRACSIS - Prognosis and Risk in Acute Coronary Syndromes In Sweden (RRID:SCR_000615) Copy   

•   Source: SciCrunch Registry

http://www.diabetestrialnet.org/biobank/

Provides investigators with the opportunity to obtain on-demand biological samples from selected individuals that TrialNet has developed through the longitudinal monitoring of individuals at risk for the development of type 1 diabetes within the Natural History study. Exploratory research is encouraged under this initiative. Studies must use TrialNet screened subjects, and cannot interfere with ongoing clinical trials or studies. Investigators can select the clinical characteristics needed for their study as well as the sample type and collection frequency. Although many Living Biobank studies may be implemented through cost-sharing with the TrialNet network, special sample collections and visits outside of the normal visit schedules will incur additional costs which should be covered by the approved applicant. In addition, some studies may require effort from the TrialNet coordinating center, with costs covered by the approved ancillary study. Living biobank studies will be evaluated with careful consideration for their potential impact on the objectives and performance of the TrialNet Natural History study. To protect the interests of TrialNet, each living biobank study must be reviewed and approved by the Ancillary Studies Committee before its initiation. All approved living biobank studies will be reviewed yearly to evaluate their progress, and impact on TrialNet as a whole. TrialNet welcomes the submission of living biobank studies as an adjunct to ongoing protocols.

Proper citation: Living Biobank (RRID:SCR_001510) Copy   

•   Source: SciCrunch Registry

http://www.futuremedicine.com/doi/pdf/10.2217/17410541.4.4.389

THIS RESOURCE IS NOT IN SERVICE, documented August 9, 2016. A genetic biobank in Taizhou, China which plans to collect five million samples in 10 years.

Proper citation: Taizhou Biobank (RRID:SCR_000935) Copy   

•   Source: SciCrunch Registry

http://www.utsouthwestern.edu/labs/acute-liver/

Clinical research network for gathering prospective data and bio-samples on acute liver failure in adults since 1998. Clinical histories and laboratory and outcome data are available. Sample types include serum, plasma, urine, DNA, and liver tissue.

Proper citation: Acute Liver Failure Study Group (RRID:SCR_001463) Copy   

•   Source: SciCrunch Registry

https://abctb.org.au/abctbNew2/default.aspx

A tissue bank which houses and supplies cancerous tissue for use by the research community. Along with tissue, the bank collects clinical history, lifestyle factors, breast pathology, treatment information, and follow up information.

Proper citation: Australia Breast Cancer Tissue Bank (RRID:SCR_000926) Copy   

•   Source: SciCrunch Registry

https://www.taburit.co.il/en/

A blood bank that operates as the marketing arm for the family cord blood banking operations of Sheba Medical Center. It is the largest medical center in the Middle East with a 24/7 call center to answer questions. The center provides collection kits, supervises the collection process, and transports the collected blood to the Sheba Cord Blood Bank.

Proper citation: Taburit Umbilical Cord Blood Bank (RRID:SCR_000920) Copy   

•   Source: SciCrunch Registry

http://www.biobank.unisi.it/Elencorett.asp

Data and biospecimen from Rett Syndrome patients shared with the scientific community with the ability to visualize the list of available samples and select those with specific clinical and molecular features. It also contains information on biospecimen samples from x-linked retardation, microdeletion, duplication syndromes, autosomal MR, and retinoblastoma. The bank is active since 1998 and it is located in the Medical Genetics Unit, at the University Hospital of Siena. The bank is divided in three distinct sections: # Rett Syndrome. This section contains samples from patients affected by Rett syndrome, a neurodegenerative disease affecting almost exclusively girls with an estimated frequency of 1:10000-15000 live born. By accessing the section users can see a list of all patients available with their phenotype, the specific MECP2 or CDKL5 mutation if known and the kind of biological samples available for each patient. The availability of this large panel of patients is potentially important for the clarification of the molecular bases of Rett syndrome. In fact, a 20-30 of Rett cases do not have MECP2 or CDKL5 mutations. These patients might bear intronic/promoter MECP2 or CDKL5 mutations or they might have alterations in one or more genes different from MECP2 or CDKL5, as suggested by the identification of various chromosomal rearrangements. To confirm a causative role of these rearrangements, and to identify the relevant gene/s, it is important to collect a great number of patients in which to search for overlapping rearrangements or point mutations in candidate genes. # X-Linked Mental Retardation. This section contains samples collected by the centers belonging to the Italian network on X-linked mental retardation, which includes the laboratory of bank curators (for specific information on the network goals and organization, go to the section page). Mental retardation (MR) is the most frequent cause of serious handicap in humans with an estimated prevalence of 0,3-0,5 for moderate to severe MR (IQ<50) which increases to 1-1,5 when mild MR (IQ 50-70) is included. It is calculated that about 20-25 of mentally retarded males have a mutation in a gene on the X chromosome (X-linked mental retardation). X-linked mental retardation is a genetically heterogeneous condition. This is particularly true for the non-syndromic form (MRX), where MR is the only consistent clinical finding and no distinctive features between patients exist. In this situation the only possibility to group patients from different families is represented by linkage analysis, which needs the availability of large families. However, families linked to the same region demonstrate different causative genes. In these conditions, the number of patients available for analysis is a discriminating factor since a large number of patients need to be tested in order to fully confirm or exclude the involvement of a gene in MRX. # Other. This section of the bank contains biological materials and clinical data of patients with other genetic disorders (different from Rett and X-linked mental retardation). Part of this section is dedicated to Alport syndrome. Services: * Isolation of leukocytes from human peripheral blood samples * Establishment of EBV transformed lymphoblastoid cell lines from human peripheral blood leukocytes. * DNA extraction. * Plasma isolation. * Storage: ** Cryo-preservation of transformed cell lines and primary leukocytes at 135��C ** Storage of DNA at 20 degrees C ** Storage of plasma at 20 degrees C * Distribution of the stored biological samples.

Proper citation: Italian Rett Syndrome database (RRID:SCR_002000) Copy   

•   Source: SciCrunch Registry

http://www.ohsu.edu/xd/research/centers-institutes/octri/current-projects/ohsu-biolibrary/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 9, 2023.A Joint Project between Oregon Clinical and Translational Research Institute (OCTRI) and the Knight Cancer Institute, the OHSU Biolibrary provides information on campus collections of biospecimens originating from OHSU patients. The Biolibrary Search Engine is a user-friendly, online search tool that allows OHSU researchers to search for suitable biospecimen samples. As of October 2010, the Biolibrary Search Engine contains data on over 500,000 biospecimens. The Search Engine accesses data from the OHSU Cancer Registry, the Department of Pathology, and the OCTRI Research Data Warehouse. You must be connected to the OHSU network to access the Search Engine. The Search Engine is accessible on Internet Explorer through WTS connection to the OHSU network.

Proper citation: OHSU Biolibrary (RRID:SCR_004282) Copy   

•   Source: SciCrunch Registry

http://www.hipsci.org/

A UK national induced pluripotent stem (iPS) cell resource that will create and characterize more than 1000 human iPSCs from healthy and diseased tissue for use in cellular genetic studies. Between 2013 and 2016 they aim to generate iPS cells from over 500 healthy individuals and 500 individuals with genetic disease. They will then use these cells to discover how genomic variation impacts on cellular phenotype and identify new disease mechanisms. Strong links with NHS investigators will ensure that studies on the disease-associated cell lines will be linked to extensive clinical information. Further key features of the project are an open access model of data sharing; engagement of the wider clinical genetics community in selecting patient samples; and provision of dedicated laboratory space for collaborative cell phenotyping and differentiation.

Proper citation: HipSci (RRID:SCR_003909) Copy   

•   Source: SciCrunch Registry

http://vitiligobiobank.org/

A non-profit collection of biological samples and detailed associated clinical data, designed to facilitate medical research into vitiligo, a devastating skin disease that is much neglected. They collect, store and analyze biological samples throughout the network of collaborators in 11 countries, using standard collection protocols and unified patient record, which are then made available to the scientific community and research organizations investigating pathogeneses, diagnostics, new treatments, and ultimately a cure for vitiligo. The core asset is a large collection of well-organized hair, blood, serum and DNA samples, integrated with comprehensive and anonymized patient records.

Proper citation: Vitiligo Biobank (RRID:SCR_003863) Copy   

•   Source: SciCrunch Registry

http://www.mountsinai.on.ca/allograft/

Mount Sinai Allograft Technologies, a department of Mount Sinai Hospital formerly known as the The Rubinoff Bone Bank, has been a leader in advanced tissue innovations since 1972. We are committed to providing the highest quality bone and tissue allograft products as well as continued innovation in the development of allograft implants for transplantation. We are dedicated to meeting all surgical needs and to exceed all client expectations. We work closely with the Trillium Gift of Life Network to promote their mission of increasing donor awareness and to ensure that the wishes of Ontario donor families' are carried out with the utmost care and respect. Our allograft implants are 100% Ontario produced, human allograft tissues. To produce the safest and highest quality Canadian produced allograft implants, Mount Sinai Allograft Technologies leverages the expertise of a variety of medical experts, state-of-the art laboratory testing, proven bio-processing techniques, validated irradiation methods and preferred packaging systems.

Proper citation: Mount Sinai Allograft Technologies (RRID:SCR_003586) Copy   

•   Source: SciCrunch Registry

http://www.alsconsortium.org/neals_samples.php

Repository of serum, plasma, cerebrospinal fluid (CSF), whole blood, extracted DNA, and urine samples from NEALS and Massachusetts General Hospital Neurology Clinical Trials Unit (NCTU) research studies of amyotrophic lateral sclerosis (ALS). Samples from this repository are available to researchers for the purpose of furthering the understanding of ALS or developing disease biomarkers. Applications will be accepted at any time, but the committee meets bi-monthly to review applications. The application requires a brief description and scientific justification for the use of the samples. Priority will be given to members of NEALS and investigators from sites that participated in the collection of samples. Investigators must provide IRB approval from their institution. Applications may be submitted to: mghneuroclinicaltrialsunit (at) partners.org (please cc: tlincoln (at) partners.org) NEALS collects an administrative fee of $1,000 at the time of application submission to offset processing costs. If an application for samples is denied, 80% of the administrative fee will be returned. The administrative fee is waived for NEALS members. Checks may be made payable to: The Northeast ALS Consortium.

Proper citation: NEALS Sample Repository (RRID:SCR_004271) Copy   

•   Source: SciCrunch Registry

http://bbmri-eric.eu

BBMRI is a pan-European and internationally broadly accessible research infrastructure and a network of existing and de novo biobanks and biomolecular resources. The infrastructure will include samples from patients and healthy persons, representing different European populations (with links to epidemiological and health care information), molecular genomic resources and biocomputational tools to optimally exploit this resource for global biomedical research. During the past 3 years BBMRI has grown into a 53-member consortium with over 280 associated organizations (largely biobanks) from over 30 countries, making it the largest research infrastructure project in Europe. During the preparatory phase the concept of a functional pan-European biobank was formulated and has now been presented to Member States of the European Union and for associated states for approval and funding. BBMRI will form an interface between specimens and data (from patients and European populations) and top-level biological and medical research. This can only be achieved through a distributed research infrastructure with operational units in all participating Member States. BBMRI will be implemented under the ERIC (European Research Infrastructure Consortium) legal entity. BBMRI-ERIC foresees headquarters (central coordination) in Graz, Austria, responsible for coordination of the activities of National Nodes established in participating countries. BBMRI is in the process of submitting its application to the European Commission for a legal status under the ERIC regulation, with an expected start date at the end of 2011. Major synergism, gain of statistical power and economy of scale will be achieved by interlinking, standardizing and harmonizing - sometimes even just cross-referencing - a large variety of well-qualified, up-to date, existing and de novo national resources. The network should cover (1) major European biobanks with blood, serum, tissue or other biological samples, (2) molecular methods resource centers for human and model organisms of biomedical relevance, (3) and biocomputing centers to ensure that databases of samples in the repositories are dynamically linked to existing databases and to scientific literature as well as to statistical expertise. Catalog of European Biobanks www.bbmriportal.eu Username: guest / Password: catalogue The catalogue is intended to be used as a reference for scientists seeking information about biological samples and data suitable for their research. The BBMRI catalogue of European Biobanks provides a high-level description of Europe''s biobanks characteristics using a portal solution managing metadata and aggregate data of biobanks. The catalogue can be queried by country, by biobank, by ICD-groups, by specimen types, by specific strengths, by funding and more. A search function is available for all data.

Proper citation: Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) (RRID:SCR_004226) Copy   

•   Source: SciCrunch Registry

http://www.acceleratedcure.org/impact/repository

A repository of biological samples and data from people with multiple sclerosis, selected other demyelinating diseases, and unaffected controls. The repository not only provides much-needed samples and data to researchers studying MS and other diseases, but also aggregates the results from all of these studies so that they can be analyzed collectively, leading to new findings and breakthroughs. The repository collects blood, DNA, and imaging once per year. The repository currently includes samples and data from over 2,700 subjects with Multiple Sclerosis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Transverse Myelitis, Optic Neuritis, and Clinically Isolated Syndromes, as well as controls. Blood samples are provided as aliquots as serum, plasma, DNA, RNA, and lymphocytes and each sample is accompanied by more than 40 pages of clinical and epidemiological data contributed by the subject and the enrolling neurologist.

Proper citation: Accelerated Cure Project MS Repository (RRID:SCR_004208) Copy   

•   Source: SciCrunch Registry

http://www.medunigraz.at/en/biobank

Biobank Graz is a non-profit central Medical University of Graz (MUG) service facility that provides the logistics and infrastructure to optimally support MUG research teams in the collection, processing and storage of biological samples and their associated data. In the course of this, special attention is given to sample and data quality and to the protection of the individual rights of patients. Samples from selected patients at the Graz LKH-University Clinical Centre, who have signed an informed consent declaration, are deposited in Biobank Graz. This means that excess tissue and blood samples are collected and placed in storage. The samples are harvested in the course of routine interventions undertaken by the different departments and institutes of the Graz LKH-University Clinical Centre and approved for use in research projects only after the completion of all necessary laboratory and histopathological analyses. No additional material is removed: in other words, there are no associated drawbacks whatsoever for the patients involved. Biobank Graz operates a quality management system according to ISO 9001:2008 and offers the following services for the processing and storage of biological samples and the handling of data: * Consistently high sample quality through the processing of samples using standardized methods in accordance with written working instructions (SOPs) * Efficient use of resources through the building of shared infrastructure and the development of optimized processes * A high degree of reliability provided by the storage of samples in 24/7 - monitored storage systems. * Processing and storage of all data in accordance with data protection legislation. Biobank Graz comprises both population-based and disease-focused collections of biological materials. It currently contains approx. 3.8 mio samples from approx. 1.2 mio patients representing a nonselected patient group characteristic of central Europe. Because the Institute of Pathology was, until 2003, the exclusive pathology service provider for major parts of the province of Styria, including its capital Graz (population approx. 1.2 mio people), samples from all human diseases, treated by surgery or diagnosed by biopsy, are included in the collection at their natural frequency of occurrence and thus represent cancers and non-cancerous diseases from all organs, and from all age groups. The scientific value of the existing tissue collection is, thus, not only determined by its size and technical homogeneity (all samples have been processed in a single institute under constant conditions for more than 20 years), but also by its population-based character. These features provide ideal opportunities for epidemiological studies and allow the validation of biomarkers for the identification of specific diseases and determination of their response to treatment. Prospectively collected tissues, blood samples and clinical data comprise, on the one hand, randomly selected samples from all diseases and patient groups to provide sufficient numbers of samples for the evaluation of the disease-specificity of any gene or biomarker. On the other hand, Biobank Graz adopts a disease-focused approach for selected diseases (such as breast, colon and liver cancers as well as some metabolic diseases) through the collection of a range of different human biological samples of highest quality and detailed clinical follow-up data. Graz Medical University established the Biobank to provide improved and sustainable access to biological samples and related (clinical) data both for its own academic research and for external research projects of academic and industrial partners. It is a major interest of the university to initiate co-operative research projects. Biological samples and data are available to external institutions performing high-quality research projects which comply with the Biobank''s ethical and legal framework according to the access rules (Contact: COO Karine Sargsyan, MD, PhD).

Proper citation: Biobank Graz (RRID:SCR_004245) Copy   

•   Source: SciCrunch Registry

http://genomics.ucsf.edu/dna-bank

The DNA Bank accepts the clinical samples from projects that have been approved by the Committee on Human Research (CHR). Genomic DNA isolation is performed utilizing standardized and quality controlled Gentra Systems'' PureGene DNA isolation system or Qiagen Kits. The quantity and quality of the genomic DNA isolate is determined by 260/280 UV spectrophotometery. Following isolation and quality assessment, DNA can be aliquoted into a normalized concentration. The preparation of aliquots serves to allow ready distribution of DNA samples to both the client laboratory and their collaborators and to preclude excessive routine freezing and thawing of the primary DNA isolate, a practice which is well known to result in notable degradation of genomic DNA stocks. All samples are stored in alarmed Revco ultra-low freezers at -80����?����?����?��������C. All of the ultra-low freezer units utilized by the DNA Bank are monitored by a temperature sensitive alarm system that provides 24 hour oversight. In the event of a power outage, all freezers are on an emergency back-up electrical generator.

Proper citation: UCSF DNA Bank (RRID:SCR_004248) Copy   

•   Source: SciCrunch Registry

http://www.genomeutwin.org/index.htm

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 29, 2016. Study of genetic and life-style risk factors associated with common diseases based on analysis of European twins. The population cohorts used in the Genomeutwin study consist of Danish, Finnish, Italian, Dutch, English, Australian and Swedish twins and the MORGAM population cohort. This project will apply and develop new molecular and statistical strategies to analyze unique European twin and other population cohorts to define and characterize the genetic, environmental and life-style components in the background of health problems like obesity, migraine, coronary heart disease and stroke, representing major health care problems worldwide. The participating 8 twin cohorts form a collection of over 0.6 million pairs of twins. Tens of thousands of DNA samples with informed consents for genetic studies of common diseases have already been stored from these population-based twin cohorts. Studies targeted to cardiovascular traits are now being undertaken in MORGAM, a prospective case-cohort study. MORGAM cohorts include approximately 6000 individuals, drawn from population-based cohorts consisting of more than 80 000 participants who have donated DNA samples.

Proper citation: GenomEUtwin (RRID:SCR_002843) Copy   

•   Source: SciCrunch Registry

http://specimencentral.com/

World's open biospecimen research database where biobanks and biomedical researchers meet to exchange human biospecimen needs and supply: whole blood, serum, plasma, solid tissue samples and more. The connection is accelerated so researchers save valuable time and money and tissue banks utilize inventory. The pace of specimen procurement remains unacceptably slow to the biomedical research community. Specimen Central is the foremost global resource to aid biomedical researchers in expediting their search for high quality human biospecimens, tissues, samples and specimens. They facilitate your search for blood, whole blood, buccal swab, DNA, RNA, protein, cell lines, plasma, serum, RBC, white cells, buffy coat, fluid, marrow, urine, stem cells, and solid tissue such as tumor, tumor and biopsy materials spanning all manner of common and rare pathologies and indications including Alzheimer's, basal cell carcinoma, bladder cancer, bone cancer, brain cancer, breast cancer, cerebrospinal fluid, amniotic fluid, colorectal cancer, colon cancer, hodgkins and non-hodgkins lymphoma, kidney/renal cancer, leukemia, liver cancer, lung cancer, melanoma, multiple sclerosis, myeloma neuroblastoma, neurodegenerative diseases, ovarian cancer, pancreatic cancer, prostate cancer, urinary cancer. This includes adult and pediatric indications. Specimen Central users specify a number of variables in their Specimen Requests, including preparation, preservation and handling requirements such as cryo-preserved, FFPE (Formalin-fixed paraffin-embedded), formalin, frozen, refrigerated, OCT, snap frozen, paraffin block, fresh, prospective, autopsy or cadaveric, etc. Many users require clinically annotated date associated with their specimens, as well as documentation of IRB or ethics committee approval and informed consents. For Researchers Most specimen databases require researchers to waste time and effort entering lengthy registrations and search queries that yield poor results, if anything. Specimen Central solves this problem by having tissue banks search for you. From years to months, months to weeks, and weeks to days, Specimen Central seeks to reduce delays and costs in the research & development life cycle by expediting connections between demand and supply. For Biobanks The capital costs of maintaining a biobank infrastructure are substantial and growing. Biobanks use Specimen Central as a marketing tool to augment their business development efforts. By routinely checking Specimen Central's Specimen Requests, biobanks can uncover market demand for their inventories and develop new connections and revenue streams to defray costs. Specimen Central supplements - not displaces - the efforts of your sales representatives, agents, brokers and commercial partners.

Proper citation: SpecimenCentral.com (RRID:SCR_003536) Copy   

•   Source: SciCrunch Registry

http://www.roswellpark.edu/shared-resources/data-bank-and-biorepository

Collects and provides de-identified biospecimens and associated epidemiological and clinical data to meet the scientific needs of investigators. Newly diagnosed patients are asked to contribute data and specimens to the DBBR prior to treatment. Other patients with who have benign disease or advanced disease and have undergone treatment are also enrolled based on anticipated use of data and samples for research. Additionally, non-patients (family members and friends of patients and community members) with no personal history of cancer are asked to participate in the biorepository as controls. Specimens and data are procured with protected health information (PHI) and de-identified prior to distribution to investigators with hypothesis driven IRB reviewed studies. An extensive data collection and management system is in place to track informed consent, questionnaire collection and follow up, epidemiological questionnaire data, clinical data, biospecimens and their derivatives. Research Services * Availability of a bank of prospectively collected blood specimens (serum, plasma, buffy coat, red blood cells and DNA) from cancer patients, high risk individuals and healthy controls for research. * Collection, linking and distribution of epidemiologic and clinical data with biospecimens. * Study-specific biospecimen and data procurement to meet the needs of individual studies, including: ** Participant identification, eligibility screening and informed consent ** Serial biospecimen procurement prior to and throughout treatment ** Study specific collection of biospecimens other than blood (buccal cells, sputum, and urine) ** Procurement and distribution of fresh biospecimens ** Collection of extended clinical and risk factor data

Proper citation: Roswell Park Data Bank and BioRepository (RRID:SCR_003607) Copy   

•   Source: SciCrunch Registry